Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results-论文-万方医学网

首页> > Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

导出原文传递

翻译打印收藏纠错

第一作者： Laura C.,Coates

作者： Laura C.,Coates ^[1] ; Philip,Mease ^[2] ; Andris,Kronbergs ^[3] ; Cameron,Helt ^[4] ; David,Sandoval ^[5] ; So Young,Park ^[6] ; Bernard,Combe ; Peter,Nash ; Atul,Deodhar

作者单位： Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,University of Oxford ^[1] Swedish Medical Center/Providence St,Joseph Health and University of Washington ^[2] Eli Lilly and Company ^[3] University of Montpellier ^[4] Department of Medicine,University of Queensland ^[5] Division of Arthritis and Rheumatic Diseases,Oregon Health & Science University ^[6]

关键词 Antirheumatic agents Ixekizumab Methotrexate Psoriatic arthritis

发布时间 2022-11-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

相似文献

同项目论文

相关期刊

检索历史 清除

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

相似文献

同项目论文

相关期刊

检索历史清除